NovoCureSTU:038 +3.27%69 FCF Yield % is -2.63 as of Jul. 02, 2026. GuruFocus rates STU:038 with a GF Score™ of 69/100 and a GF Value™ of €16.27 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 858 Medical Devices & Instruments companies, NovoCure ranks worse than 59.56% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for NovoCure's FCF Yield % or its related term are showing as below:
STU:038'
s FCF Yield % Range Over the Past 10 Years
Min: -26.17 Med: -1.06 Max: 1.25
Current: -2.63
During the past 13 years, the highest FCF Yield % of NovoCure was 1.25%. The lowest was -26.17%. And the median was -1.06%.
STU:038's FCF Yield % is ranked worse than 59.56% of 858
companies
in the Medical Devices & Instruments industry
Industry Median: -0.445
vs STU:038: -2.63
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
NovoCure FCF Yield % Related Terms
NovoCure FCF Yield % Historical Data
* Premium members only.
The historical data trend for NovoCure's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:038 vs ALMR, UFPT, NEOG: FCF Yield % Comparison
For the Medical Devices subindustry, NovoCure's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's FCF Yield % distribution charts can be found below:
* The bar in red indicates where NovoCure's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure (STU:038) has a FCF Yield % of -2.63 as of Jul. 02, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on NovoCure and its competitors. According to the industry distribution chart, NovoCure ranks #511 out of 858 companies in the Medical Devices & Instruments industry, placing it in the top 59.6%.
Is NovoCure's FCF Yield % too high?
NovoCure's current FCF Yield % is -2.63. Based on the distribution chart, NovoCure ranks #511 out of 858 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NovoCure has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's FCF Yield % compare to ALMR and UFPT?
According to the Medical Devices & Instruments industry distribution chart, NovoCure ranks #511 out of 858 companies for FCF Yield %. This places NovoCure in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on NovoCure and its competitors. NovoCure's current FCF Yield % is -2.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (STU:038) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.27, compared to a current price of €13.75 — trading 15.5% below its estimated fair value. The current FCF Yield % is -2.63. NovoCure's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For NovoCure (STU:038), the current FCF Yield % is -2.63 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NovoCure (STU:038) Overvalued in 2026?
Based on GuruFocus' analysis, NovoCure stock appears to be undervalued.
The current stock price of €13.75 is trading 15.5% below its estimated GF Value™ of €16.27.
GuruFocus considers NovoCure to be Modestly Undervalued.
Key valuation signals for STU:038:
FCF Yield %: -2.63
GF Value™: €16.27 vs. price of €13.75 (15.5% below fair value)
No single metric tells the full story. See the STU:038 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
69GF Score
Get the complete analysis for STU:038
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:038 has been successfully added to your 
